Milestone Analyses

This work will analyze genome-wide association of common genetic variants for Parkinson’s disease risk across Northern European, Icelandic, Finnish, and Ashkenazi Jewish ancestry groups. The work will include downstream analysis of cell type and tissue type gene expression enrichment of candidate genes, and other immediate downstream analyses.

This work will use genome-wide association of common genetic variants to identify the genetic determinants of age at onset of Parkinson’s disease. It will assess the correlation between genetic risk for disease and genetic modifiers of age at onset of disease.

This effort will use genome-wide association to test and identify genetic variation that influences the penetrance and age at onset of Parkinson’s disease linked to LRRK2 mutations. This will include both single-variant genome-wide association and polygenic risk score testing

This effort will use genome-wide association to test and identify genetic variation that influences the penetrance and age at onset of Parkinson’s disease linked to GBA1 mutations. This will include both single-variant genome-wide association and polygenic risk score testing.

This effort will center on a large-scale multi-ancestry meta-analysis of Parkinson’s disease, including individuals of European, Asian, Latin American and African ancestry, using data from existing and emerging association studies in these groups.

This effort will include genome-wide association separately in male and female Parkinson’s cases of European ancestry, aiming to determine if there are differences in autosomal genetic risk between males and females.

This work will analyze genome-wide association of common genetic variants for Parkinson’s disease risk in individuals with West African ancestry, including those with substantial admixed West African ancestry.

This study will perform genome-wide association testing of the role of common variants in motor progression of Parkinson’s disease in European ancestry cases. It will include quantitative progression and time to event analysis for features extracted from MDS UPDRS-3, Hoehn and Yahr, and self-reported motor outcomes.

This work will center on genome wide association testing of risk for Parkinson’s disease in individuals from Latin America.

This effort will investigate the rare variant genetic component of Parkinson’s disease risk using array, whole genome, and whole exome sequencing data. This work will use single variant and gene burden tests in an attempt to identify genetic risk variants and disease linked genes cases of European ancestry.

This study will comprise a comprehensive, multi-ancestry investigation of rare causative and known risk variants in PD and parkinsonism-related genes across the GP2 dataset. This will include individuals of European, Middle Eastern, Ashkenazi Jewish, African, and Asian ancestries, and Latino individuals.

This Chromosome X-wide analysis will center on identifying X-linked genetic risk factors for Parkinson’s disease across available ancestral groups.

This GWAS will compare heterozygous affected vs. unaffected carriers of heterozygous pathogenic variants in PRKN and PINK1 to test the hypothesis that additional genetic factors impact affected status in such heterozygous carriers. This has currently included ~800 individuals of European ancestry, to which another ~300 datasets from recently identified carriers of CNVs will be added (and other ethnicities later if sample size permits).